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Genomics is the study of all the genes in a person, as well as 
the interactions of those genes with each other and a person’s 
physical and social environment. All people are 99.9% identical 
in genetic makeup, but differences in the remaining 0.1% hold 
important clues about health and disease. The study of genomics 
is likely to help doctors and other health care professionals 
understand why some people get sick from certain infections, 
environmental factors, and behaviors while others do not. This 
information could lead to new and better ways to improve 
health and prevent diseases for individuals and populations. 
Public health genomics is a multidisciplinary field focused 
on the effective and responsible translation of genome-based 
knowledge and technologies into public health and clinical 
practice to improve population health. It uses population
CDC’s Response 
data on genetic variation and gene-environment interactions
to develop evidence-based tools for improving health and 
preventing disease. 
“Translating the knowledge we are gaining from
�
gene discoveries into practical clinical and public
�
health applications will be critical for realizing the 

potential of personalized health care and improving
�
the health of the nation.”
�
Muin J. Khoury, MD, PhD
Director, National Office of Public Health Genomics, CDC 
CDC works to integrate human genomics into public health 
research, policy, and programs. CDC’s National Office of Public 
Health Genomics (NOPHG) strives to improve interventions 
designed to prevent disease and improve the public’s health by 
helping to develop and distribute evidence-based knowledge 
and tools in 
• Human genome epidemiology. 
• Family health history. 
• Genetic and genomic testing.
Human Genome Epidemiology 
Human genome epidemiology (HuGE) examines the role 
of genetics in disease and health and helps to identify links 
between genes and other factors, such as diet and environmental 
exposures, in populations. Research in these areas can help us 
understand which populations might be more likely to develop 
disease as well as design interventions to improve treatment and 
health outcomes. 
Population-Based Studies 
Since 2008, NOPHG and the National Center for Influenza 
and Respiratory Diseases have funded the Pediatric Acute Lung 
Injury and Sepsis Investigators (PALISI) Network to conduct 
a genetic epidemiology study of life-threatening and fatal flu 
in children and young adults. As of August 2009, PALISI has 
enrolled more than 130 people who had severe or fatal flu, with 
40% presumed to have H1N1 flu. Preliminary findings from 
the study will be published this year. 
In 2009, NOPHG continued to fund five CDC genomics-
related projects that focused on genetic aspects of folic acid 
supplementation before pregnancy, environmental hazards that 
affect autism spectrum disorder, infant blood lead concentra-
tions and auditory brainstem response, worker susceptibility 
to noise-induced hearing loss, and chronic beryllium disease. 
NOPHG also continued to work with other groups at CDC to 
examine the links between selected genetic variants and disease 
outcomes in data from the third National Health and Nutrition 
Examination Survey (NHANES III). Studies published in 2009 
focused on associations between selected genetic variants, blood 
lead levels, and blood pressure and between selected gene
variants and lead exposure and cognitive function. 
New Tools and Resources for Researchers 
Two new tools were developed in the online database HuGE 
Navigator (http://www.hugenavigator.net) to help researchers 
search and select data from all published studies that examine 
genetic variation across the human genome. These tools also 
provide prevalence estimates for selected genetic variants in the 
U.S. population. In addition to these new tools, the second edi-
tion of Human Genome Epidemiology: Building the Evidence for 
Using Genetic Information to Improve Health and Prevent Disease



















The Human Genome Epidemiology Network (HuGENet™) 
developed new guidelines that were simultaneously published
in eight journals to help researchers standardize results and 
interpret evidence found in human genetic association studies. 
Family Health History 
Family history reflects individuals’ genes and the behaviors and 
environmental factors they share with their family members. 
Family history is a risk factor for many chronic diseases (such 
as cancer, coronary heart disease, and diabetes), making it an 
important tool for identifying people at increased risk for these 
diseases. NOPHG projects in this area include the following: 
• In 2009, results of NOPHG’s Family Healthware™ evalua-
tion study showed that people perceive their risk for cancer 
to be significantly higher than for other diseases when 
they base their risk on family history. Men worried most 
about getting heart disease, while women worried most 
about breast cancer, followed by heart disease. Diabetes was 
perceived to be the least severe condition. Heart disease was 
perceived to be the most controllable condition compared 
with cancer, which was perceived to be the least controllable. 
Compared with men, women had higher levels of percep-
tions of risk and worry for several diseases. 
• As part of a national work group on family health history
led by the U.S. Department of Health and Human Services, 
NOPHG is helping to enhance My Family Health Portrait, 
an Internet-based tool for collecting family health histories, 
so that it also assesses disease risk and provides advice based 
on risk and family history. Other projects are underway with 
Microsoft HealthVault and My HealtheVet, an electronic
health system for the Veteran’s Administration. 
• In 2009 and early 2010, four CDC studies on family history 
and health were published or accepted for publication. The 
topics of the studies included family history of asthma, early-
onset stroke/transient ischemic attack, and diabetes. One 
study examined family history of diabetes and the likelihood
of developing gestational diabetes, the prevalence of metabolic 
syndrome, and the ability to detect undiagnosed diabetes
in adults. 
Genetic and Genomic Testing 
Researchers have developed genetic tests for more than 1,800 
diseases. Most tests look at single genes and are used to diagnose 
rare genetic disorders, such as fragile X syndrome and Duchenne 
muscular dystrophy. However, a growing number of tests look 
at multiple genes that may increase or decrease a person’s risk 
for common diseases, such as cancer or diabetes. In addition, 
some genetic tests look at rare genetic variants, such as those 
responsible for some hereditary breast and ovarian cancers.
Such tests have the potential to help prevent common diseases 
and improve the health of individuals and populations. 
Evaluation of Genetic Tests 
In 2009, the Evaluation of Genomic Applications in Practice
and Prevention (EGAPP) Working Group established by 
NOPHG released three new evidence-based recommendations 
that address genetic testing for various clinical scenarios involving 
breast and colorectal cancer. The EGAPP Working Group 
recommended genetic testing for Lynch syndrome (a type of 
inherited colorectal cancer) for patients with newly diagnosed 
colorectal cancer to help relatives of these patients determine 
their disease risk. However, not enough evidence was available
for the EGAPP Working Group to recommend either for or
against the use of gene expression profiling for tumors to improve 
health outcomes in specific populations of women with breast 
cancer or for the routine use of UGT1A1 genotyping to deter-
mine the use of irinotecan in chemotherapy for patients with 
metastatic colorectal cancer. 
In 2010, the EGAPP Working Group will release recommen-
dations on genetic testing in adults with a history of venous 
thromboembolism and on the use of genomic profiling to assess 
risk for cardiovascular disease. 
Translation of Genomic Applications into Practice 
In 2009, NOPHG, the National Institutes of Health, and other 
stakeholders established the Genomic Applications in Practice 
and Prevention Network (GAPPNet™) to effectively and respon-
sibly translate evidence-based genetic and genomic tests into 
practice. GAPPNet™ is made up of more than 100 stakeholders.
In 2009, genomics translations projects funded by NOPHG 
achieved the following: 
• Developed a Web-based tool for clinicians and policy mak-
ers to assess the potential benefits and harms of new genetic 
tests. 
• Developed a pharmacogenomics program to educate health 


















potential benefits and harms of pharmacogenomic tests. 
• Planned a program to educate health care providers about 
the benefits of documenting patients’ family histories, identi-
fying family history factors considered high risk, referring 
patients to genetic consultation, and using genetic testing. 
• Promoted and helped to increase health insurance coverage 
for genetic testing of BRCA1/2 mutations associated with 
hereditary breast and ovarian cancer in 3 of the 24 health 
plans in Michigan. 
• Set up a genomics surveillance program in Oregon that uses 
data from the Behavioral Risk Factor Surveillance System, 
Medicaid claims, the Oregon State Cancer Registry, and 
genetics counseling and testing services to monitor awareness 
and use of genomic tests for cancer and documentation
of family history by health care providers and the public. 
In 2008, NOPHG used two surveys to learn more about U.S. 
health care providers’ and consumers’ awareness and use of
personal genome tests. These tests are developed on the basis
of limited scientific information and may not provide valid
or useful results for people who are tested. Of the 5,399 con-
sumers surveyed, 22% were aware of the tests and 0.3% had 
used them. Of the 1,880 health care providers surveyed, 42% 
were aware of the tests, with dermatologists and pediatricians 
most aware (50%) and obstetrician/gynecologists least aware 
(36%). 
Among health care providers who were aware of the tests, 42% 
had at least one patient who had asked questions in the past 
year about having such a test, and 15% had at least one patient 
who had brought the results of a personal genome test to them 
for discussion. Among this 15% (mainly internists and family 
doctors), 75% said the test results changed some aspect of the 
patient’s care, such as screening tests offered, medications or 
dosages prescribed, lifestyle changes recommended, frequency
of follow-up appointments planned, or diagnoses made. 
In 2009, the Healthy People 2020 Federal Interagency Work-
group approved two 10-year national objectives to (1) increase 
the proportion of people with newly diagnosed colorectal cancer 
who receive genetic testing to identify Lynch syndrome or 
other familial colorectal cancer syndromes and (2) increase the 
proportion of women with a family history of breast or ovarian 
cancer who receive genetic counseling. 
Future Directions 
In 2010, NOPHG will enhance national efforts to translate 
evidence-based genomics applications—such as genetic tests, 
technologies, and family history—into better, more targeted 
interventions for preventing disease, improving treatments, and 
reducing health disparities. To achieve these objectives, 
NOPHG is 
• Developing tools for researchers and health care providers 
that provide evidence summaries on the validity and useful-
ness of specific genomic applications and the potential harms 
and benefits of these applications. 
• Starting a new initiative called Genetics for Early Disease 
Detection and Intervention to educate health care providers 
and public health practitioners on the use of clinical, genetic, 
and family history information for early diagnosis of rare 
genetic disorders and common diseases with the goal of 
improving health outcomes. 
• Enhancing its efforts to integrate genomics into national and 
state surveillance systems and surveys and using NHANES 
to generate and combine data on the distribution of genetic 
risk factors in the U.S. population and its subgroups. 
• Increasing efforts to integrate genomics into public health 
investigations. For little additional cost, public health
practitioners can collect genetic information to learn more 
about why some people develop disease. 
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